Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Prolonged Multimodal Analgesia Strategy on Postoperative Pain in Patients Undergoing Spine Surgery

NCT07935252 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07935252 Not yet recruiting Not applicable 132 participants (estimated) Started 2026

Follow this trial by email Email me the PDF

Get the NCT07935252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started November 2026. Interventional study, 132 participants (estimated). Lead sponsor Beijing Tiantan Hospital. Primary measure: Incidence of moderate-to-severe chronic pain at 3 months postoperatively.

How it compares

2,875 similar trials: same condition (Postoperative Pain) and phase

Enrollment

This trial
132
Middle half
52 to 100
Median
70
Trials with a value
2,874

Months from start to completion

This trial
16.7
Middle half
7 to 23
Median
12
Trials with a value
2,856

Sites

This trial
Not reported
Middle half
1 to 1
Median
1
Trials with a value
2,622
Posted results or a linked paper 44% 1,258 of 2,875 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Prolonged Multimodal Analgesia Strategy on Postoperative Pain in Patients Undergoing Spine Surgery
Lead sponsor
Beijing Tiantan Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 10, 2026
Completion date
April 1, 2028
Enrollment
132 (estimated)
Sites
Not reported

Conditions

MeSH condition names; the registry's own terms follow.

Postoperative Pain

Registry terms: acute and chronic postsurgical pain

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Lead sponsor
Beijing Tiantan Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Prolonged Multimodal Analgesia Group Experimental Esketamine, dexmedetomidine, pregabalin
Show registry wording

Pre-operative (1 hour): pregabalin 150mg; Intraoperative: Esketamine 0.09 mg/kg/h pumping; Post-operative: Esketamine combined with dexmedetomidine PCA: the esketamine dosage is 0.06 mg/kg/h, dexmedetomidine dosage is 1.5 μg/kg, and the PCA pump is used for 48 hours; Pregabalin 75 mg bid in 1-7 days and Pregabalin 75 mg qd in 8-21days. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail.

drugs:Esketamine, dexmedetomidine, pregabalin device:Patient Controlled Analgesia(PCA)

Conventional Analgesia Group Active comparator Sufentanil
Show registry wording

The participant will be administrated by Sulfentanil PCA (1.5μg/kg) in postoperative 48h. The anesthesiologist may adjust the drug dosage as appropriate based on the patient's condition, and all medications administered must be documented in detail.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Incidence of moderate-to-severe chronic pain at 3 months postoperatively postoperative 3 months

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Sufentanil 21 Orange Book patentsPatent cliff February 2, 2038 (Orange Book patent)
    • US 11672738; expires February 2, 2038; assignee Vertical
    • US 8945592; expires July 29, 2031; assignee Talphera, Inc.
    • US 8202535; expires October 22, 2030; assignee Talphera, Inc.
    • US 8865743; expires October 22, 2030; assignee Talphera, Inc.
    • US 10896751; expires March 16, 2030; assignee Talphera, Inc.
    • +16 more patents

Lead sponsor's other trials

Beijing Tiantan Hospital, most recent start first.

Similar trials

Same condition (Postoperative Pain) and phase, most recent start first.